At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 12, 2026 at 16:15 ET
Rocket Pharmaceuticals reported Q3 2026 financial results: net loss of $49.2 million ($0.43 per share) vs. $50.3 million loss ($0.45) a year ago, roughly in line with the $-0.41 consensus. The key stock-moving news is FDA alignment on the pivotal Phase 2 trial for RP-A501 in Danon disease, with dosing completion expected by mid-2027 and topline results in mid-2028. Cash of $279.4 million plus a $150 million Hercules credit facility extends runway into Q3 2028, with potential extension into 2029.
- FDA alignment on pivotal Phase 2 trial of RP-A501 in Danon disease: 12-patient population, 12-month co-primary endpoints, dosing completion by mid-2027, topline results mid-2028
- Q3 2026 net loss of $49.2 million ($0.43 per share) vs. $50.3 million loss ($0.45) in Q3 2025
- Cash, cash equivalents and investments of $279.4 million as of September 30, 2026
- Hercules Capital credit facility of up to $150 million; $35 million drawn at closing
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access